Browsing Tag
Owen Hughes
2 posts
Why AnaptysBio’s new CFO hire may matter more than a routine biotech appointment
AnaptysBio is no longer a classic biotech pipeline bet. Christopher Murphy’s CFO appointment tests whether ANAB can execute as a royalty vehicle.
Ligand Pharmaceuticals (LGND) to acquire XOMA Royalty (XOMA) for $739m as biotech royalty consolidation accelerates
Ligand is buying XOMA for $739 million in cash. The real story sits inside a CVR tied to a $19.7 billion Johnson and Johnson royalty fight.